Differences in frequency distribution of HLA-A2 subtypes between north american and italian white melanoma patients: Relevance for epitope specific vaccination protocols

Journal of Immunotherapy

Volumn 19, Issue 5, 1996, Pages 357-363

  Player, Mary Anne ^a   Barracchini, Kathleen C ^b   Simonis, Toni B ^b   Rivoltini, Licia ^b   Arienti, Flavio ^b   Castelli, Chiara ^b   Mazzocchi, Arabella ^b   Belli, Filiberto ^b   Parmiani, Giorgio ^b   Marineola, Francesco M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HLA; Melanoma; Melanoma antigens

Indexed keywords

HLA A2 ANTIGEN; MELANOMA ANTIGEN; MELANOMA VACCINE; PEPTIDE;

ANTIGEN SPECIFICITY; ARTICLE; CAUCASIAN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE FREQUENCY; HLA TYPING; HUMAN; HUMAN CELL; ITALY; MAJOR CLINICAL STUDY; MELANOMA; NORTH AMERICA; PRIORITY JOURNAL; SEROTYPING; VACCINATION;

EID: 10544242201     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199609000-00005     Document Type: Article

References (43)

1. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
3. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
5. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments], J Exp Med 1994;180:35.
6. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
7. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
8. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995; 181:1261]. J Exp Med 1995;181:799-804.
9. Kang X, Kawakami Y, el-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor infiltrating lymphocytes. J Immunol 1995;155:1343-8.
10. Robbins PF, el-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995; 154: 5944-50.
11. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
12. Wolfel T, Schneider J, Meyer zum Buschenfelde KH, Rammensee HG, Rotzschke O, Falk K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1. Int J Cancer 1994; 57: 413-8.
13. Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. A deca-peptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ue-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994;153:5650-8.
14. Marineóla FM, Venzon D, White D, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy [published erratum appears in Cancer Res 1993;53:3846], Cancer Res 1992;52:6561-6.
15. Lee TD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In: Lee J, ed. The HLA system. New York: Springer-Verlag, 1990:141-78.
16. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: DeVita VT, Heilman S, Rosenberg SA, eds. Cancer, principles and practice of oncology. Philadelphia: JB Lippincott, 1993:1612-61.
17. Fernandez-Vina MA, Falco M, Sun Y, Stastny P. DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of A28. Hum Immunol 1992;33:163-73.
18. Krausa P, Brywka M, Savage D, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995;45:223-31.
19. Anonymous. Ancestry of the population by state. In: U.S. Bureau of the Census, ed. 1980 Census of population. Washington, D.C.: U.S. Government Printing Office, 1983:1.
20. Lopez de Castro JA. HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol Today 1989; 10:239-46.
21. del Guercio MF, Sidney J, Hermanson G, et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995;154:685-93.
22. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum Immunol 1994;39:155-62.
23. Fruci D, Rovero P, Falasca G, et al. Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. Hum Immunol 1993; 38:187-92.
24. Rotzschke O, Falk K, Stevanovic S, Jung G, Rammensee HG. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur J Immunol 1992;22:2453-6.
25. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
26. Rivoltini L, Loftus DJ, Barracchini K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and gplOO by HLA-A2 subtypes: implications for peptide-based immunotherapy. J Immunol 1996;156:3882-91.
27. Hopkins KA, van Leeuwen A, Tardiff GN, LeFor WM. Lymphotoxicity testing. In: Zachary AA, Teresi GA, eds. ASHI laboratory manual. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, 1990:195-9.
28. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 1993;90:2842-5.
29. Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 1994;43:7-17.
30. Marineóla FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
31. Sadler AM, Petronzelli F, Krausa P, et al. Low-resolution DNA typing for HLA-B using sequence-specific primers in allele or group-specific ARMS/PCR. Tissue Antigens 1994;44:148-54.
32. Marineóla FM, Shamamian P, Rivoltini L, et al. HLA associations in the anti-tumor response against malignant melanoma. J Immunother 1996;18:242-52.
33. Piazza A, Menozzi P, Cavalli-Sforza LL. The HLA-A, B gene frequencies in the world: migration or selection? Hum Immunol 1980; 1:297-304.
34. Williams F, Middleton D, Savage D, Wilson D, Gorodezky C, Agrawal S. HLA-A*02 sub-typing by PCR-SSOP. Hum Immunol 1996;47:7.
35. Fan L, Yao Z, Ehret T, et al. Significant HLA-A*02 allelic variation revealed in Chinese and Caucasian populations. Hum Immunol 1996;47:7.
36. Mazzi B, Zino E, Bordignon C, Benazzi E, Fleischhauer K. Molecular analysis of HLA-A*02 subtype frequencies in the population of Northern Italy. Hum Immunol 1996;47:7.
37. Santos P, Martinho A, Fonseca AM, et al. HLA-A*02 subtyping in a Portuguese population. Hum Immunol 1996;47:7.
38. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human mouse class I major histocompatibility complex. J Exp Med 1991; 173:1007-15.
39. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
40. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156:3308-14.
41. Carreno BM, Koenig S, Coligan JE, Biddison WE. The peptide binding specificity of HLA class I molecules is largely allele specific and non-overlapping. Mol Immunol 1992;29:1131-40.
42. McMichael AJ, Gotch FM, Santos-Aguado J, Strominger JL. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:9194-8.
43. Nikolic-Zugic J, Carbone FR. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant. Eur J Immunol 1990;20:2431-7.